Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 13/20 | 0.43 |
| ▸ | CCR3 | P51677 | 13/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322746 | 1.00 | HRH1 (0.43) | HRH1CCR3KCNH2OPRK1MAOA | |
| SCHEMBL6329232 | 0.78 | GAA (0.49) | KCNH2MEN1LMNAKMT2A | |
| SCHEMBL6329235 | 0.78 | GAA (0.49) | KCNH2MEN1LMNAKMT2A | |
| SCHEMBL6322581 | 0.76 | KDM4E (0.44) | HRH1MEN1LMNAKMT2A | |
| SCHEMBL6322573 | 0.76 | KDM4E (0.44) | HRH1MEN1LMNAKMT2A | |
| SCHEMBL5789326 | 0.73 | HRH3 (0.59) | HRH1CCR3KCNH2MAOAMAOB | |
| SCHEMBL5789325 | 0.73 | HRH3 (0.59) | HRH1CCR3KCNH2MAOAMAOB | |
| SCHEMBL6321430 | 0.70 | SIGMAR1 (0.37) | — | |
| SCHEMBL4966743 | 0.69 | HRH1 (0.82) | HRH1CCR3KCNH2OPRK1 | |
| SCHEMBL6330742 | 0.69 | HPGD (0.39) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | HRH3, HRH4, HRH1 | HRH1 3/4885CCR3 548/4885KCNH2 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.